Residency · Residency · Neurology
Rapidly Progressive Dementias and Prion Disease
Introduction
Rapidly progressive dementia (RPD) is defined as a dementia syndrome progressing from first symptoms to severe impairment within one to two years. While prion diseases are the prototypical cause of RPD, a substantial proportion of cases have treatable etiologies including autoimmune, infectious, metabolic, and neoplastic conditions. The neurologist must pursue an urgent, systematic evaluation because early diagnosis of a reversible cause can be life-saving.
Differential Diagnosis of RPD
The Mnemonic: VITAMINS
The VITAMINS mnemonic provides a comprehensive framework. "V" stands for vascular causes such as cerebral vasculitis, multiple strokes, and CADASIL. "I" represents infectious etiologies including prion disease, HIV, neurosyphilis, Whipple disease, and progressive multifocal leukoencephalopathy. "T" covers toxic-metabolic causes such as Wernicke encephalopathy, heavy metals, hepatic encephalopathy, and Wilson disease. "A" is for autoimmune conditions including autoimmune encephalitis (anti-NMDAR, anti-LGI1, anti-CASPR2), Hashimoto encephalopathy, neurosarcoidosis, CNS vasculitis, and paraneoplastic syndromes. "M" represents metastatic and neoplastic causes including CNS lymphoma, carcinomatous meningitis, intravascular lymphoma, and gliomatosis cerebri. The second "I" covers iatrogenic causes such as medication side effects, radiation injury, and chemotherapy-related leukoencephalopathy. "N" stands for neurodegenerative conditions including Creutzfeldt-Jakob disease, rapidly progressive AD, DLB, FTD, and corticobasal syndrome. "S" encompasses systemic and seizure-related causes such as nonconvulsive status epilepticus, systemic illness (sepsis, organ failure), and depression (pseudodementia).
Diagnostic Approach
Urgent Evaluation
The evaluation begins with a detailed history addressing the timeline of decline, associated symptoms (seizures, movement disorders, psychiatric symptoms, systemic features), medication review, exposure history, and family history. Blood tests should include CBC, CMP, ESR, CRP, TSH, vitamin B12, RPR/FTA-ABS, HIV, ANA, complement, thyroid antibodies (anti-TPO, anti-TG), paraneoplastic antibody panel, copper/ceruloplasmin, heavy metals, and ACE level.
MRI brain with contrast is essential, with DWI sequences being critical for detecting cortical ribboning in CJD, medial temporal/limbic involvement in autoimmune encephalitis, and white matter disease patterns. CSF analysis should include cell count, protein, glucose, cytology, flow cytometry, bacterial and fungal cultures, HSV PCR, VDRL, oligoclonal bands, and IgG index. CSF-specific tests for CJD include 14-3-3 protein, total tau (which is markedly elevated), and RT-QuIC (real-time quaking-induced conversion), which has a sensitivity of 92-95% and specificity near 100%. Anti-neuronal antibodies should be tested in both serum and CSF. EEG may reveal periodic sharp wave complexes in CJD, extreme delta brush in anti-NMDAR encephalitis, focal or generalized slowing, or nonconvulsive status epilepticus. CT of the chest, abdomen, and pelvis or PET-CT should be performed to evaluate for occult malignancy if a paraneoplastic syndrome is suspected.
Prion Diseases
General Principles
Prion diseases are caused by misfolding of normal cellular prion protein (PrPC) into the pathogenic isoform (PrPSc). PrPSc acts as a template, inducing conformational change in adjacent PrPC molecules, consistent with the protein-only hypothesis. The characteristic pathology includes spongiform change, neuronal loss, astrogliosis, and prion protein deposition. No effective treatment exists, and these diseases are universally fatal. Decontamination of surgical instruments requires specific protocols, including autoclaving at 134 degrees C for 18 minutes or treatment with 1N NaOH.
Sporadic Creutzfeldt-Jakob Disease (sCJD)
Sporadic CJD is the most common prion disease, accounting for 85-90% of CJD cases, with an incidence of 1-2 per million per year worldwide. The mean age of onset is 60-65 years, and median survival is only 5-6 months. Clinical features include rapidly progressive dementia, myoclonus (stimulus-sensitive startle myoclonus in 80-90%), cerebellar ataxia, visual disturbances (including cortical blindness in the Heidenhain variant), pyramidal and extrapyramidal signs, and akinetic mutism in late stages. Subtypes are defined by the PRNP codon 129 polymorphism (M/M, M/V, V/V) and PrPSc type (type 1 or 2), with MM1 being the most common classic phenotype.
| Test | Finding in sCJD | Sensitivity | Specificity |
|---|---|---|---|
| MRI DWI | Cortical ribboning, caudate/putamen signal | 91–96% | High |
| CSF RT-QuIC | Positive prion seeding activity | 92–95% | 98–100% |
| CSF 14-3-3 | Elevated | ~85% | Low (non-specific) |
| CSF total tau | Markedly elevated (>1,150 pg/mL) | ~90% | Moderate |
| EEG | Periodic sharp wave complexes (1–2 Hz) | 60–70% (MM1 subtype) | Moderate |
Diagnostic Evaluation for sCJD
MRI with DWI and FLAIR sequences shows cortical ribboning (high signal in the cortex on DWI) and/or caudate and putamen signal abnormality. DWI is more sensitive than FLAIR, with a sensitivity of 91-96%. CSF RT-QuIC is the most specific diagnostic test, with a sensitivity of 92-95% and specificity of 98-100%, and has largely replaced brain biopsy for diagnosis. CSF 14-3-3 protein is sensitive but not specific, as it is elevated in many causes of rapid neuronal injury. CSF total tau is markedly elevated, often exceeding 1,150 pg/mL, and is more specific than 14-3-3. EEG shows periodic sharp wave complexes (PSWCs) at 1-2 Hz in 60-70% of sCJD cases, especially the MM1 subtype, with sensitivity decreasing in non-MM1 subtypes.
Genetic Prion Diseases
Genetic prion diseases account for 10-15% of prion diseases and are caused by autosomal dominant mutations in the PRNP gene. Genetic CJD has a phenotype similar to sCJD, with the most common mutations being E200K and V210I. Fatal familial insomnia (FFI) results from the D178N mutation with M at codon 129 in cis and presents with progressive insomnia, dysautonomia, motor signs, and dementia, with characteristic selective thalamic atrophy. Gerstmann-Straussler-Scheinker (GSS) syndrome, associated with P102L and other mutations, presents as slowly progressive cerebellar ataxia and cognitive decline with longer survival measured in years. PRNP gene sequencing should be performed in all suspected prion disease cases.
Acquired Prion Diseases
Variant CJD (vCJD), acquired from BSE-contaminated beef, has a younger onset (median age 28) with early psychiatric symptoms, painful dysesthesias, and the characteristic "pulvinar sign" on MRI (bilateral pulvinar hyperintensity); it is now very rare. Iatrogenic CJD historically resulted from contaminated growth hormone, dura mater grafts, corneal transplants, and neurosurgical instruments, but is now exceedingly rare due to preventive measures. Kuru was transmitted through ritualistic cannibalism in Papua New Guinea and is of historical significance.
Other Rapidly Progressive Prion-Like Dementias
Rapidly progressive Alzheimer disease accounts for 10-30% of AD cases and must be distinguished from CJD. AD biomarkers (amyloid PET, CSF Abeta42, p-tau) and RT-QuIC can differentiate the two conditions.
Autoimmune Causes of RPD (Important Treatable Mimics)
Anti-NMDA receptor encephalitis typically affects young women and presents with psychiatric symptoms, seizures, movement disorders, and autonomic instability; it is diagnosed by CSF antibody testing and treated with immunotherapy. Anti-LGI1 encephalitis affects older adults and presents with faciobrachial dystonic seizures, hyponatremia, and limbic encephalitis; it is responsive to immunotherapy. Hashimoto encephalopathy (SREAT) is characterized by elevated anti-TPO antibodies and a fluctuating encephalopathy that is steroid-responsive. Paraneoplastic encephalitis, associated with anti-Hu, anti-Ma2, and anti-AMPAR antibodies, requires a search for underlying malignancy.
Clinical Pearls
Not all rapidly progressive dementias are prion disease; up to 20-25% of RPD cases referred to prion surveillance centers ultimately have a treatable or non-prion diagnosis. CSF RT-QuIC has transformed CJD diagnosis, and its near-perfect specificity makes brain biopsy rarely necessary. MRI DWI is the most sensitive imaging modality for CJD, and DWI sequences should always be included in the evaluation of RPD. Autoimmune encephalitis is the most important treatable mimic of CJD, and anti-neuronal antibody panels should always be sent in both serum and CSF. PRNP sequencing should be performed in all cases of suspected prion disease, as genetic forms are identified in 10-15% and have implications for genetic counseling of at-risk family members.
References
- Geschwind MD. Rapidly progressive dementia. Continuum (Minneap Minn). 2016;22(2):510-537.
- Hermann P, Appleby B, Brandel JP, et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol. 2021;20(3):235-246.
- Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(Pt 10):2659-2668.
- McGuire LI, Peden AH, Orru CD, et al. Real-time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2012;72(2):278-285.